PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of comintbioLink to Publisher's site
 
Commun Integr Biol. 2017; 10(5-6): e1389359.
Published online 2017 November 26. doi:  10.1080/19420889.2017.1389359
PMCID: PMC5731511

Potential for intermittent stimulation of nucleus basalis of Meynert to impact treatment of alzheimer's disease

ABSTRACT

The brain's cholinergic arousal pathways decline in parallel with the brain's executive functions in aging and Alzheimer's Disease. The frontline and currently most effective approach to treating Alzheimer's disease is the administration of cholinesterase inhibitors, which, in a dose dependent manner, improve the symptoms of cognitive decline over the first months of treatment before further decline occurs. We recently showed that intermittent deep brain stimulation of the nucleus basalis of Meynert improves working memory function in young adult monkeys, and that this improvement depended on cholinergic function. Within minutes, the monkeys’ ability to remember stimuli over a delay period improved. Over months, the monkeys performed the working memory task better even in the absence of stimulation. Here, we show historical data from our monkey colony in which more than two dozen animals have performed the same behavioral task to asymptotic performance levels. Using a distribution based on our historical data, we estimate that the monkeys receiving intermittent stimulation leapt over the performance level of 32–44 percent of peer animals in the first several months after stimulation was initiated. Implications for a parallel increase in cognitive function for early Alzheimer's patients are discussed.

KEYWORDS: Alzheimer's Disease, acetylcholine, deep brain stimulation

The cholinergic hypothesis of cognitive deficits related to age and Alzheimer's Disease dates to the 1970s, when scientists began to notice clear correlations between the losses in cognition and cholinergic function.1–3 Physiological abnormalities observed in Alzheimer's Disease include choline transport, acetylcholine release, expression of cholinergic receptors, neurotrophin support, and perhaps axonal transport.4,5 Cholinesterase inhibitors and some cholinergic agonists improve the cognitive deficits associated with Alzheimer's Disease, while some anticholinergic agents worsen specific cognitive deficits observed in the dementia. The relationship between cholinergic function and cognition are regionally restricted to the brain's cholinergic arousal pathways, which notably include the pedunculopontine and laterodorsal tegmental nucleus, the nucleus basalis of Meynert and substantia innominata, the medial septum, and the diagonal band of Broca.6

The frontline treatment for Alzheimer's Disease is the administration of cholinesterase inhibitors,7,8 the most prevalent of which is donepezil (Aricept). Subjects are typically prescribed 5 mg/day of donepezil, then increase their dosage, if tolerated, to 10 mg, and finally up to 23 mg. The highest dose leads over 30% of patients to discontinue use from the side effect profile which most notably includes nausea, vomiting, and related gastrointestinal symptoms.9,10 In patients who tolerate the highest dose, cognitive symptoms improve across several cognitive domains over a three month period. By one year after treatment, cognitive function has returned to the baseline that existed before donepezil use, and declines with aging thereafter.11

We explored the contribution of cholinergic modulation to executive function by combining deep brain stimulation of the nucleus basalis of Meynert with a working memory task in the Rhesus monkey.12 We found that concurrent intermittent stimulation boosted working memory function. Although animals had been trained to asymptotic levels of performance before initiating stimulation, in the following months their working memory improved even in the absence of concurrent stimulation. The magnitude of the long-term effect was approximately four times as large as the magnitude of the short-term effect. However, the changes in performance in these monkeys could not be easily translated to the projected impact on a human who could receive the same treatment.

We therefore compiled a database of working memory performance of 25 Rhesus monkeys from our colony, all of which had performed the same task to asymptotic performance levels for thousands of behavioral trials. For each animal, we found a working memory delay interval for which the percentage of correct trials was as close to 80% as possible, and always between 70 and 90 percent correct, at the conclusion of asymptotic training. We scaled that delay to estimate the interval at which that animal would have been correct in 80% of the trials by interpolation and comparison with memory performance in our published work.12 Lastly, we superimposed the long-term changes in memory performance of our three animals, using an interval for which they were correct on 80% of the trials, on this historic distribution. As can be seen in Fig. 1, the delays changed from 1.5 to 8 seconds, 3 to 10 seconds, and 6 to 30 seconds. These changes corresponded to percentile shifts of 32, 36, and 44 percent, and spanned a large range of the distribution of working memory abilities.

Figure 1.
Shifts in working memory delay as percentile changes. The working memory delay at which animals were 80% correct was estimated based on data from 25 historical records from our colony. The change in percentile of three animals trained with intermittent ...

The remaining question is how a 30–40 percentile shift in performance would alter age-related decline. Cholinergic modulation of cognition is reasonably comparable in older and younger subjects.13 In working memory, a 30 percentile change would make an average human 65 year old have a superior working memory to an average 25 year old, thereby erasing all age related decline in working memory.14 The earliest deficits differentiating an Alzheimer's Disease patient from a control are in delayed recall, a measure of episodic memory,15 and the deficit is a little more than one standard deviation. The question of how intermittent stimulation could impact such a patient group remains an open one, with many caveats about the potential pitfalls of translation. However, the potential to markedly improve cognition in Alzheimer's patients is a straightforward prediction from these studies.

Funding

This work was supported by NIH [grant number R01MH097695].

References

1. Bartus RT. On neurodegenerative diseases, models, and treatment strategies: Lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol. 2000;163:495–529. doi: PMID:10833325.10.1006/exnr.2000.7397. [PubMed] [Cross Ref]
2. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science [Internet]. 1982. [cited 2017. September27];215:1237–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7058341. [PubMed]
3. Coyle J, Price D, DeLong M Alzheimer's disease: a disorder of cortical cholinergic innervation. Science (80- ) [Internet]. 1983. [cited 2017. September27];219:1184–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/6338589. doi:10.1126/science.6338589. [PubMed] [Cross Ref]
4. Sarter M, Bruno JP Cognitive functions of cortical acetylcholine: toward a unifying hypothesis. Brain Res Rev. 1997;23:28–46. doi: PMID:9063585.10.1016/S0165-0173(96)00009-4. [PubMed] [Cross Ref]
5. Terry AV Jr, Buccafusco JJ The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther. 2003;306:821–7. doi: PMID:12805474.10.1124/jpet.102.041616. [PubMed] [Cross Ref]
6. Saper CB, Scammell TE, Lu J Hypothalamic regulation of sleep and circadian rhythms. Nature [Internet]. 2005. [cited 2017. June4];437:1257–63. Available from: http://www.nature.com/doifinder/10.1038/nature04284. doi:10.1038/nature04284. [PubMed] [Cross Ref]
7. Small GW, Rabins PV, Barry PP, Buckholtz NS, DeKosky ST, Ferris SH, Finkel SI, Gwyther LP, Khachaturian ZS, Lebowitz BD, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA [Internet]. 1997. [cited 2017. September27];278:1363–71. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.1997.03550160083043. doi:10.1001/jama.1997.03550160083043. [PubMed] [Cross Ref]
8. Wimo A, Ballard C, Brayne C, Gauthier S, Handels R, Jones RW, Jonsson L, Khachaturian AS, Kramberger M Health economic evaluation of treatments for Alzheimer′s disease: Impact of new diagnostic criteria. J Intern Med [Internet]. 2014. [cited 2017. September27];275:304–16. Available from: http://doi.wiley.com/10.1111/joim.12167. doi:10.1111/joim.12167. [PubMed] [Cross Ref]
9. Cummings JL, Geldmacher D, Farlow M, Sabbagh M, Christensen D, Betz P, Donepezil 23 Mg Expert Working G. High-Dose donepezil (23 mg/day) for the treatment of moderate and severe alzheimer's disease: drug profile and clinical guidelines. Cns Neurosci Ther [Internet]. 2013. [cited 2017. June2];19:294–301. Available from: http://onlinelibrary.wiley.com/doi/10.1111/cns.12076/full. doi:10.1111/cns.12076. [PubMed] [Cross Ref]
10. Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, Brand-Schieber E, Zou H, Hsu T, Satlin A Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. Clin Ther [Internet]. 2010. [cited 2017. April11];32:1234–51. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0149291810002249. doi:10.1016/j.clinthera.2010.06.019. [PMC free article] [PubMed] [Cross Ref]
11. Yoshida T, Ha-Kawa S, Yoshimura M, Nobuhara K, Kinoshita T, Sawada S Effectiveness of treatment with donepezil hydrochloride and changes in regional cerebral blood flow in patients with Alzheimer's disease. Ann Nucl Med. 2007;21:257–65. doi: PMID:17634843.10.1007/s12149-007-0022-2. [PubMed] [Cross Ref]
12. Liu R, Crawford J, Callahan PM, Terry AV, Constantinidis C, Blake DT Intermittent Stimulation of the Nucleus Basalis of Meynert Improves Working Memory in Adult Monkeys. Curr. Biol. 2017. Sep 11;27(17):2640-2646.e4.doi:.10.1016/j.cub.2017.07.021 [PubMed] [Cross Ref]
13. Buccafusco JJ. Cognitive Pharmacology in Aging Macaques [Internet]. CRC Press/Taylor & Francis; 2006. [cited 2016. April18]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21204362.
14. Myerson J, Emery L, White DA, Hale S Effects of age, domain, and processing demands on memory span: Evidence for differential decline. Aging, Neuropsychol Cogn (Neuropsychology, Dev Cogn Sect B) [Internet]. 2003. [cited 2017. September27];10:20–7. Available from: http://www.tandfonline.com/doi/abs/10.1076/anec.10.1.20.13454. doi:10.1076/anec.10.1.20.13454. [Cross Ref]
15. Chen P, Ratcliff G, Belle SH, Cauley JA, DeKosky ST, Ganguli M Cognitive tests that best discriminate between presymptomatic AD and those who remain nondemented. Neurology [Internet]. 2000. [cited 2017. September28];55:1847–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11134384. doi:10.1212/WNL.55.12.1847. [PubMed] [Cross Ref]

Articles from Communicative & Integrative Biology are provided here courtesy of Taylor & Francis